Oral β-Lactam Pairs for the Treatment of Mycobacterium avium Complex Pulmonary Disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38150401.
- Also identified by DOI 10.1093/infdis/jiad591 and PMC identifier 11326814.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cure rates for pulmonary disease caused by the Mycobacterium avium complex (MAC) are poor. While β-lactam are front line antibiotics against Mycobacterium abscessus pulmonary disease, they have not been used or recommended to treat MAC lung infections. Through a comprehensive screen of oral β-lactams, we have discovered that selected pairs combining either a penem/carbapenem or penicillin with a cephalosporin are strongly bactericidal at clinically achieved concentrations. These dual β-lactam combinations include tebipenem and sulopenem, both in phase 3, and Food and Drug Administration-approved amoxicillin and cefuroxime. They could therefore immediately enter clinical trials or clinical practice.
Medical subject headings
- Mycobacterium avium Complex
- beta-Lactams
- Mycobacterium avium-intracellulare Infection
- Anti-Bacterial Agents